Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 6/20 | 0.38 |
| ▸ | FEN1 | P39748 | 6/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18985433 | 0.86 | TBK1 (0.39) | TBK1FEN1PIK3CAPIK3CDPIK3CB | |
| SCHEMBL18985660 | 0.85 | PIK3CD (0.46) | TBK1FEN1PIK3CAPIK3CDPIK3CB | |
| SCHEMBL19005012 | 0.82 | PIK3CD (0.41) | TBK1FEN1PIK3CAPIK3CDPIK3CB | |
| SCHEMBL19668078 | 0.81 | FFAR1 (0.38) | TBK1FEN1PIK3CAPIK3CDPIK3CB | |
| SCHEMBL18985752 | 0.80 | PIK3CD (0.43) | TBK1PIK3CAPIK3CDPIK3CBPI4KA | |
| SCHEMBL19004902 | 0.78 | PIK3CD (0.40) | TBK1FEN1PIK3CAPIK3CDPIK3CB | |
| SCHEMBL19668107 | 0.78 | LRRK2 (0.34) | TBK1PIK3CAPIK3CDPIK3CBPI4KA | |
| SCHEMBL19005256 | 0.74 | PIK3CD (0.39) | TBK1PIK3CAPIK3CDPIK3CBPI4KA | |
| SCHEMBL20732754 | 0.74 | ALOX5AP (0.45) | FEN1PIK3CAPIK3CDPIK3CBPI4KA | |
| SCHEMBL18985609 | 0.72 | MAPT (0.48) | TBK1PIK3CAPIK3CDPIK3CBPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3390387-B1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | Bayer Pharma AG (DE) | 2021-11-17 | — | — | EP | disclosed |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-19 | — | — | US | disclosed |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-19 | — | — | US | disclosed |
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-14 | — | — | US | disclosed |
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-14 | — | — | US | disclosed |
| EP-3390387-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017102091-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | CCNI, CCNT2, CDK2 | TBK1 1468/4885FEN1 1072/4885PIK3CA 241/4885 |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | CCNI, CCNT2, CDK2 | TBK1 1468/4885FEN1 1072/4885PIK3CA 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.